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ABSTRACT
Dietary guidelines commonly recommend that children aged >2 y consume reduced-fat dairy products rather than regular- or whole-fat dairy. In
adults, most studies have not found the consumption of whole-fat dairy products to be associated with increased cardiometabolic or adiposity risk.
Associations in children could differ due to growth and development. We systematically reviewed the literature in indexed, peer-reviewed journals
to summarize pediatric studies (children aged from 2 to 18 y) assessing associations between whole- and reduced-fat dairy intake and measures of
adiposity as well as biomarkers of cardiometabolic disease risk, including the serum lipid profile, blood pressure, low-grade chronic inflammation,
oxidative stress, and measures of glucose homeostasis. For the purposes of this review, a “whole-fat” dairy product was defined as a product with
the natural fat content, whereas a “reduced-fat”dairy product was defined as a product with some or all of the fat removed (including “low-fat”and
“skim”versions). A total of 29 journal articles met our criteria for inclusion. The majority were conducted in the United States and were prospective
or cross-sectional observational studies, with only 1 randomized controlled trial. Studies were consistent in reporting that whole-fat dairy products
were not associated with increased measures of weight gain or adiposity. Most evidence indicated that consumption of whole-fat dairy was not
associated with increased cardiometabolic risk, although a change from whole-fat to reduced-fat dairy improved outcomes for some risk factors in
1 study. Taken as awhole, the limited literature in this field is not consistent with dietary guidelines recommending that children consumepreferably
reduced-fat dairy products. High-quality randomized controlled trials in children that directly compare the effects of whole-fat compared with
reduced-fat dairy intake on measures of adiposity or biomarkers of cardiometabolic disease risk are needed to provide better quality evidence in
this area. Adv Nutr 2020;00:1–23.
Keywords: dairy, low-fat, regular-fat, skim milk, whole milk, children, pediatric, overweight, cholesterol
Introduction
Dietary guidelines in the United States, Australia, the
UnitedKingdom, andother countries recommend that adults
and children consume predominantly reduced-fat, rather
than whole-fat (also known as full-fat or regular-fat) dairy
products (1–5). Reduced-fat dairy products are traditionally
recommended over whole-fat dairy products due to their
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lower energy and saturated fat content, which is thought to
limit the risk of excessive energy intake, weight gain, and
cardiometabolic disease (6).
Although the hypothesis that removing fat from dairy
foods could benefit body weight and cardiometabolic risk
does have theoretical plausibility, it does not seem to be sup-
ported by currently available data. Consumption of whole-
fat dairy products is not associated with the development
of obesity or cardiometabolic disease in adults, and could
even be beneficial (7–9). A review of observational studies
in adults found that dairy fat consumption is not associated
with an increased risk of weight gain, type 2 diabetes
mellitus, or cardiovascular disease (10). Another review
of observational studies found that circulating and tissue
biomarkers of habitual dairy fat intake (pentadecanoic acid,
15:0, and heptadecanoic acid, 17:0) were not associated with
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cardiovascular disease-related outcomes or type 2 diabetes
mellitus, although the authors noted limitations of these
biomarkers including uncertainty of dietary origins and
endogenous metabolism (11). Additionally, higher intakes
of whole-fat dairy foods were not associated with increased
risk of mortality in a meta-analysis (12). These results are
supported by the large, multinational Prospective Urban
Rural Epidemiology (PURE) study, which found that higher
intake of dairy fat was not associated with increased risk of
total mortality or major cardiovascular disease (13).
In adult populations, emerging evidence is challenging
the long-standing belief that consumption of whole-fat dairy
products should be avoided in favor of lower-fat varieties.
Despite whole-fat dairy foods being more energy dense (i.e.,
more energy per gram consumed), it is unclear whether
whole-fat dairy foods are less satiating per calorie consumed.
It is also possible that the combination of numerous unique
fatty acids in dairy fat, including short-chain or branched-
chain fatty acids, as well as conjugated linoleic acids and
trans-palmitoleic acid, could exert beneficial hormone-like
effects (14). In addition, milk fat globule membrane and
bioactive peptides from dairy show some potential to benefit
health, although more research is needed (15).
Consumption of dairy products, particularly milk, is
generally popular in children. Commonly considered to
be an important food group as part of a balanced diet,
dairy products are a good dietary source of nutrients for
healthy development, including protein, calcium, potassium,
phosphorus, and several vitamins. Two meta-analyses of
observational studies published in 2016 both concluded that
total dairy consumption was inversely associated with risk
of overweight and obesity in children (16, 17). Likewise, a
review of dairy consumption in children and adolescents,
with a focus on results from the Healthy Lifestyle in Europe
by Nutrition in Adolescence (HELENA) study, found that
higher consumption of milk and yogurt was associated with
improved cardiovascular risk factors (18). Similarly, a non-
systematic critical review concluded that milk and other
dairy products were consistently not associated, or inversely
associated, with indicators of adiposity in children (19). The
authors also noted that adjustment for energy intake tended
to neutralize inverse associations.
However, there is a paucity of research specifically focused
on potential differential effects of whole-fat compared with
reduced-fat dairy intake in children (17). Although the focus
of the reviews was on total dairy rather than dairy fat, studies
that were noted as evaluating both whole-fat and reduced-
fat dairy products suggested the relation between dairy and
adiposity was unlikely to vary according to fat type.
To our knowledge, there have been no published sys-
tematic reviews investigating associations between dairy fat
and types of dairy products with measures of adiposity and
cardiometabolic health in pediatric populations. Given the
changing attitudes toward whole-fat dairy consumption in
adults, it is timely to investigate this concept in children.
Consumption of dairy products might result in different
health effects in children compared with adults, due to
differing needs in growth and development. It is valuable to
consider both adiposity and cardiometabolic factors, because
both these aspects have important and often interlinking
long-term health effects.
The aim of this article is to comprehensively evaluate
the existing literature reporting associations between whole-
fat dairy consumption, including comparison with reduced-
fat dairy where available, and measures of adiposity and
cardiometabolic risk factors in children. Summarizing the
literature in this area will be informative for upcoming
dietary guideline revisions, and will also assist in identi-
fying gaps to plan future research. We investigated dairy
with differing fat content along with dairy fat and as-
sociated biomarkers, to help account for inherent factors
in dairy products that might be responsible for health
outcomes (20).
Our research questions were:
1) In children, is consumption of whole-fat dairy products or
dairy fat associated with highermeasures of adiposity? Do
associations differ for reduced-fat dairy intake?
2) In children, is consumption of whole-fat dairy products or
dairy fat associated with increased cardiometabolic risk?
Do associations differ for reduced-fat dairy intake?
Methods
This systematic review was conducted in accordance with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement. For the purposes of this
review, a “whole-fat” dairy product is defined as a product
with the natural fat content, whereas a “reduced-fat” dairy
product is defined as a product that has had some or all of
the fat removed (including “low-fat” and “skim” versions).
One study in this review (21) also included dairy foods that
are naturally low in fat, such as cottage cheese, in the low-fat
dairy category.
Search process
Searches used combinations of the search terms: Dairy OR
milk OR cheese OR yogurt OR yoghurt; AND child OR chil-
dren OR adolescence OR adolescent OR school OR boy OR
girlOR teenageORpediatricORpaediatricORpreschoolOR
youth; AND cholesterol OR LDL OR HDL OR triglycerides
OR insulinORglucoseORmetabolic syndromeORMetSOR
insulin resistanceOR insulin sensitivityOR glucose tolerance
OR glucose intolerance OR cardiometabolic OR cardio OR
metabolic OR obesity OR obese OR overweight OR body
fat OR waist OR waist-to-height OR body mass index OR
growth OR BMI OR weight OR blood pressure OR arterial
pressure.
Studies were identified in peer-reviewed journals indexed
by the databasesMEDLINE (22), PubMed (23), theCochrane
Library (24), and Embase (25) up to 30 June 2019. In
addition, Google Scholar (26) was searched for relevant
studies.
The title and abstracts were assessed by 2 researchers
(TAOS andKAS) for general relevance. The full-text versions
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of the included articles were then examined against eligibility
criteria by the same researchers, conducted independently.
The reference lists of selected articles were hand searched
by 1 researcher (TAOS) for possible inclusion in the review.
These subsequently identified articles were assessed for
inclusion (by TAOS andKAS).Where opinions differed, final
decisions on inclusion were determined by consensus during
consultation with the supervising researcher (MK). There
were no restrictions on study design.
Eligibility criteria
Studies were eligible for inclusion in this review if:
1) Subjects in the study were between 2 and 18 y of age, or
(for prospective studies) data from ages 2 to 18 y were
reported.
2) Subjects were generally healthy/representative of the gen-
eral population (including overweight/obese children).
3) The exposure included dairy fat intake or a dairy fat
biomarker, or associations reported separately for whole-
fat and reduced-fat dairy.
4) Outcomes reported included ≥1 measure of adiposity
(including BMI, body composition, body weight, BMI
categories) or cardiometabolic health (including serum
lipids, insulin sensitivity, glucose tolerance, low-grade
chronic inflammation, blood pressure, or metabolic syn-
drome).
5) Dairy intake was restricted to products derived from
ruminant animals—studies investigating breastmilk were
not included. Studies investigating specific fortified dairy
products, including formula or specific probiotic or fiber-
enriched dairy products, were not included.
6) No dietary changes other than dairy (in intervention
studies), and no complex exposures including factors
other than dairy (observational studies).
Cardiometabolic health measures
We included studies reporting data on a standard serum lipid
profile, including total cholesterol (TC), LDL cholesterol,
HDL cholesterol, and triglycerides. Although dietary
recommendations around reducing saturated fat from
dairy have focused largely on benefits to LDL cholesterol,
several studies, including the Framingham Heart Study,
have demonstrated that lipid ratios are better indicators
of cardiovascular risk than LDL cholesterol alone (27–
29). LDL cholesterol is most commonly calculated
based on TC, HDL cholesterol, and triglyceride values.
TC:HDL cholesterol can therefore be considered to provide
information in a more straightforward manner, because
both variables are measured directly (30). Furthermore,
lipid ratios are preferred over non-HDL cholesterol values
for predicting chronic disease risk, including coronary
heart disease (31) and nonalcoholic fatty liver disease
(32). In addition, consideration of the apoB to apoA-
1 ratio could also be important. ApoB is the major
protein in LDL cholesterol particles, whereas apoA-1 is
the major protein in HDL cholesterol particles. The ratio
is considered to represent the balance between atherogenic
and antiatherogenic particles. This ratio is closely related
to different cardiovascular events in prospective studies
(33), and is considered better than LDL cholesterol at
predicting cardiovascular risk (34). Although full details are
given in the tables, for the discussion we chose to focus on
the TC:HDL cholesterol ratio as well as the apoB:apoA-
1 ratio where available, rather than individual lipid
measures (35).
Both fasting glucose and insulin, and derived measures,
as well as glycated hemoglobin (HbA1c), were selected as
biomarkers of glucose metabolism in this review. Insulin is
an important regulator of glucose metabolism. The HOMA-
IR is a surrogate measure of insulin resistance using both
fasting glucose and fasting insulin. It is considered to be a
robust clinical and epidemiological tool that compares well
with more invasive models of insulin resistance (36). HbA1c
refers to the percentage of hemoglobin that is glycated,
and represents the average amount of glucose present in
the blood over the prior 3 mo. Higher values indicate
poorer glycemic control. Assessment of glucose tolerance or
insulin sensitivity using oral or intravenous glucose tolerance
tests, or euglycemic-hyperinsulinemic clamps, was also
included.
We chose to include markers of low-grade chronic
systemic inflammation in our review, because chronic in-
flammation and activation of the immune system can be
involved in the pathogenesis of cardiovascular disease and
obesity-related insulin resistance (37, 38). C-reactive protein
(CRP) is an acute-phase protein commonly used to assess
systemic inflammation. Other common measures of low-
grade chronic inflammation include the proinflammatory
cytokines IL-6 and TNF-α, both of which are secreted by
activated proinflammatory leukocytes. Higher circulating
concentrations of CRP, IL-6, and TNF-α are thought to
indicate greater activation of proinflammatory pathways in
the body.
We also chose to include data on adiponectin, a fat-
derived hormone that acts as a messenger to communicate
between adipose tissue and other organs (39). Higher
concentrations are considered to be metabolically beneficial,
because adiponectin suppresses glucose production in the
liver and enhances fatty acid oxidation in skeletal muscle
(39). The production of adiponectin is directly suppressed by
inflammatory cytokines, such asTNF-α, and adiponectin can
therefore be thought of as an inverse, adipose tissue–specific
measure of inflammation.
Dairy biomarkers
Dairy fat intake biomarkers as an additional measure of
dietary exposure are useful to provide objective information
for nutrition research, particularly because misreporting of
diet is an important source of error (40). There is no 1
accepted biomarker for dairy fat—as the most complex of
natural fats, dairy fat is comprised of ∼400 different fatty
acids (41).We focused only on those that aremost established
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FIGURE 1 Flowchart of studies included in the systematic review.
as biomarkers of dairy fat intake: pentadecanoic acid (15:0),
heptadecanoic acid (17:0), and trans-palmitoleic acid (trans-
16:1n–7) (42).
Data extraction
Information was extracted from included journals by
1 researcher (TAOS) and verified by another (KAS). Dis-
crepancies in data extraction were discussed and resolved
by consensus with the supervising author (MK). Extracted
data included the authors, year of publication, study design,
aim of study, country, year of study, sex, age and number
of participants, dietary and outcome assessments, potential
confounding factors considered, results, and conclusions.
We decided not to perform a meta-analysis as part of this
review due to the variability in exposure categorization or
nature of intervention, subject characteristics, and methods
used within the research. As has been previously noted,
differential potential for residual confounding, variation in
types of dairy foods consumed, and location-based bovine
feeding practices (pasture or grain based) all limit the ability
to compare data from different studies directly (10).
Risk of bias
Assessments of individual studies were completed by
2 researchers, in an independent manner, without knowing
the results of the other researcher. For the purposes of this
review, no sensitivity or subgroup analyses were planned;
however, publication bias was investigated by comparing
those published articles reporting statistically significant
results with those with insignificant results.
Results
Search results
A flowchart detailing the number of studies screened,
excluded, and included in the review is displayed in
Figure 1.
Included studies
A total of 29 journal articles met our criteria for inclusion
in this review, reporting data from 22 different observational
cohorts and 2 trials. Some examined measures of adipos-
ity along with cardiometabolic outcomes, whereas others
focused on one or the other. For research examining adi-
posity measures, 20 journal articles reported on whole- and
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reduced-fat dairy intakes, and a further 5 reported on dairy
fat, or whole-fat dairy intake, or whole-fat dairy clusters (i.e.,
a dietary pattern rich in whole-fat dairy) only (Table 1). For
research examining cardiometabolic risk factors, 6 journal
articles investigated whole- and reduced-fat dairy intakes,
1 investigated whole-milk consumption only, 1 investigated
milk type and amount, and 2 investigated biomarkers of dairy
fat intake (Table 2).
The ages of the children studied ranged from 2 y (49, 52,
57, 61, 62, 71) through to mid- and late adolescence (21,
51, 57, 59, 63, 72). One study followed adolescents through
to adulthood (53). The majority of studies were conducted
in the United States, with other countries contributing ≤3
studies (Argentina, Australia, Canada, Greece, Iran, Italy,
Mexico, the Netherlands, New Zealand, Sweden, and the
United Kingdom).
Sample sizes ranged from93 (73) to 13,486 (59). Two stud-
ies were intervention trials, of which only 1was a randomized
controlled trial (43). The remainder of the studies were either
prospective or cross-sectional observational studies.
Whole-fat and reduced-fat dairy and adiposity in
children
Of the studies investigating both whole- and reduced-fat
dairy, none reported a positive association between adiposity
measures and whole-fat dairy consumption. Some reported
inverse associationswith consumption of whole-fat dairy, but
not reduced-fat dairy (46, 47, 49, 50, 58, 59). Others reported
positive associations with adiposity measures for intake of
reduced-fat, but not whole-fat dairy consumption (45, 52,
59, 62).
Taking into consideration study quality, the strongest
evidence we found was a 12-wk randomized controlled trial
of 145 children from 93 Australian families who were whole-
fat dairy consumers, aged between 4 and 13 y (43). The
intervention consisted of advice to change dairy products to
reduced-fat (≤2% fat for milk and yogurt,≤25% for cheese),
whereas the control group consisted of parental advice to
replace screen activity with other sedentary activity (e.g.,
drawing, reading, or games). Families were not blinded to
the intervention. Dietary intake was assessed by three 24-h
recalls, and completed at baseline, 12 wk, and 24 wk
(although the intervention ceased at 12 wk). BMI, BMI z-
score, and waist circumference were the adiposity measures
investigated in multilevel analyses, which were adjusted for a
range of child- and family-level covariates (Table 1). Whole-
fat dairy consumption decreased from 88% to 14% of total
dairy consumed at week 12 in the intervention group, and
consumption of reduced- and low-fat products increased
by 85%. As a result, total and saturated fat intakes from
dairy foods were significantly lower in the intervention
group. No group differences were observed in total dairy
or energy intake. This study also used serum pentadecanoic
acid (15:0) concentrations, presented as the percentage of
total fatty acids, as a biomarker of dairy fat intake. The
intervention group had significantly lower pentadecanoic
acid concentrations than the comparison group at week 12,
suggesting a lower intake of dairy fat. This difference was
not significant at week 24. Despite the successful change
in the type of dairy intake, no significant differences were
seen in any measures of adiposity between the intervention
and control groups after 12 wk of intervention (mean
difference BMI= −0.16/m2, P= 0.18; BMI z-score= −0.08,
P = 0.19; waist circumference = −0.39 cm, P = 0.38) or
at the subsequent 24-wk follow-up (mean difference BMI =
−0.15/m2, P = 0.63; BMI z-score = −0.07, P = 0.51; waist
circumference = 0.30 cm, P = 0.69).
The only other trial that investigated adiposity outcomes
was a double-blind (non-randomized) controlled trial of
schoolchildren aged 6–16 y, who were usual consumers of
whole-fat milk, staying in 13 Indigenous boarding schools
in Mexico (44). School milk was provided to each child
on weekdays (2 × 200 mL/d), with schools receiving either
1) reduced-fat (2% fat) milk, or 2) skim (0.5% fat) milk,
or 3) staying on their usual whole-fat (3% fat) milk, for
a 4-mo period. The whole-fat and reduced-fat milks were
both provided as powders (and made up at the school
site), whereas the skim milk was provided fresh. To provide
data on energy and macronutrient consumption, along with
milk intake, 130 of 462 participating children (10 from
each school) completed a diet interview with plate and
glass weighing at 2 and 3 mo after baseline. Energy and
carbohydrate intake between the 3 groups did not change
differentially, although it was noted that tortilla consumption
increased in the 2% (45 g/d) and skim-milk (100 g/d,
P < 0.05) groups, compared with the whole-fat group.
Analyses were adjusted for clustering of schools but not for
any other factors. No significant differences between whole-
and reduced-fat or skim groups for any measure of adiposity
were observed after 4 mo (BMI P = 0.23 and P = 0.39,
respectively; waist circumference P = 0.13 and P = 0.22,
respectively).
In the prospective studies identified, some reported
inverse associations between measures of adiposity and
consumption of whole-fat dairy while also reporting either
no significant associations (46, 49) or a positive relation
(45, 47, 52) between reduced-fat dairy consumption and
adiposity. Follow-up time for the prospective studies was
typically ∼1–3 y, with 1 study having a 7-y follow-up (21)
and 1 following adolescents through to adulthood (53). Both
these studies with longer time frames found no significant
associations between whole- or reduced-fat dairy intake and
adiposity measures.
The prospective study to adulthood by te Velde et al.
(53) was the Amsterdam Growth and Health Longitudinal
Study, conducted in the Netherlands. Thirteen-year-olds
(n = 634) were followed up at regular intervals to the age
of 36 y (n = 374), for measures of adiposity including
BMI (overweight defined as BMI ≥25 kg/m2), waist cir-
cumference, and fat mass as determined by DXA. Intake
of dairy was grouped as either low-fat or high-fat from
dietitian-administered diet histories for the preceding 4-wk
period. The dietary assessment considered a wide range of
dairy products beyond milk, including fromage frais, butter,
12 O’Sullivan et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/advances/article-abstract/doi/10.1093/advances/nm
aa011/5760740 by guest on 23 April 2020
TA
BL
E
2
Su
m
m
ar
y
of
re
se
ar
ch
ex
am
in
in
g
da
iry
in
ta
ke
by
fa
tc
on
te
nt
w
ith
ca
rd
io
m
et
ab
ol
ic
fa
ct
or
s
in
ch
ild
re
n1
St
ud
y
an
d
re
fe
re
n
ce
Su
b
je
ct
s
O
ut
co
m
es
2
Ex
p
os
ur
e
va
ri
ab
le
s
C
on
fo
un
d
er
s
co
n
si
d
er
ed
C
on
cl
us
io
n
s3
TR
IA
LS
(2
st
ud
ie
s)
H
en
dr
ie
an
d
G
ol
le
y,
20
11
(4
3)
Ra
nd
om
iz
ed
co
nt
ro
lle
d
tr
ia
l:
12
-w
k
in
te
rv
en
tio
n
to
sw
itc
h
to
re
du
ce
d-
fa
td
ai
ry
or
no
t;
fo
llo
w
-u
p
at
24
w
k
A
us
tr
al
ia
n
ch
ild
re
n
8.
6
±
3.
0
y
(4
–1
3
y)
,4
0%
F
n
=
14
5
Co
ns
um
in
g
≥2
sv
s/
d
of
w
ho
le
-fa
td
ai
ry
at
ba
se
lin
e

TC

H
D
L-
C

LD
L-
C

TG
W
ho
le
-fa
t(
>
2%
fo
rm
ilk
an
d
yo
gu
rt
,≥
25
%
fo
rc
he
es
e)
an
d
re
du
ce
d-
fa
t(
≤2
%
fo
r
m
ilk
an
d
yo
gu
rt
,
<
25
%
ch
ee
se
)d
ai
ry
at
ba
se
lin
e,
12
w
k,
an
d
24
w
k
fro
m
3
×
24
-h
di
et
re
ca
lls
.
C
lu
st
er
in
g
of
ch
ild
re
n
w
ith
in
fa
m
ili
es
,a
ge
,s
ex
,b
as
el
in
e
BM
I-z
,f
am
ily
in
co
m
e,
pa
re
nt
al
ed
uc
at
io
n,
pa
re
nt
al
BM
I,
ba
se
lin
e
en
er
gy
.
Sw
itc
hi
ng
fro
m
w
ho
le
-t
o
re
du
ce
d-
fa
td
ai
ry
di
d
no
t
re
su
lt
in
si
gn
ifi
ca
nt
ch
an
ge
s
to
TC
,H
D
L-
C
,o
rT
G
at
12
w
k.
Sm
al
lr
ed
uc
tio
n
in
LD
L-
C
at
24
w
k
(1
2
w
k
po
st
-in
te
rv
en
tio
n)
.∗
Vi
lla
lp
an
do
et
al
.,
20
15
(4
4)
D
ou
bl
e-
bl
in
d
co
nt
ro
lle
d
tr
ia
l
Sc
ho
ol
pr
ov
id
ed
2
×
20
0
m
L
m
ilk
/d
fo
r
4
m
o
M
ex
ic
an
ch
ild
re
n
fro
m
13
bo
ar
di
ng
sc
ho
ol
s
11
±
3
y
(6
–1
6
y)
,
(%
F
no
ts
pe
ci
fie
d)
n
=
46
2
U
su
al
co
ns
um
er
s
of
w
ho
le
-fa
t
da
iry
at
ba
se
lin
e

TG

TC

H
D
L-
C

LD
L-
C

VL
D
L-
C

TC
:H
D
L

A
po
B,
ap
oA
-1

Lp
(a
)

A
po
B:
ap
oA
-1
M
ilk
pr
ov
id
ed
w
as
ei
th
er
3%
,
2%
,o
r0
.5
%
fa
t.1
30
/4
62
su
bj
ec
ts
co
m
pl
et
ed
di
et
in
te
rv
ie
w
at
2
m
o
an
d
3
m
o
af
te
rb
as
el
in
e.
C
lu
st
er
in
g
w
ith
in
sc
ho
ol
s.
A
ge
,s
ex
,B
M
I.
Sw
itc
hi
ng
fro
m
w
ho
le
-t
o
sk
im
m
ilk
re
su
lte
d
in
de
cr
ea
se
d
LD
L-
C
∗ ,
TC
∗∗
,a
po
B∗
∗ ,
bu
t
al
so
de
cr
ea
se
d
H
D
L-
C
.∗∗
N
o
ch
an
ge
to
to
ta
l:H
D
L-
C
.
Sw
itc
hi
ng
fro
m
w
ho
le
-t
o
re
du
ce
d-
fa
tm
ilk
de
cr
ea
se
d
LD
L-
C
∗ ,
ap
oA
-1
∗ ,
ap
oB
.∗∗
N
o
ch
an
ge
in
TC
:H
D
L-
C
or
ap
oB
:a
po
A
-1
.
O
BS
ER
VA
TI
O
N
A
L:
PR
O
SP
EC
TI
VE
(3
st
ud
ie
s)
Ra
in
e
St
ud
y
O
’S
ul
liv
an
et
al
.,
20
16
(5
1)
3-
y
fo
llo
w
-u
p
A
us
tr
al
ia
n
ad
ol
es
ce
nt
s
14
±
0.
2
y
at
ba
se
lin
e,
54
%
F
n
=
86
0

M
et
S4

Lo
w
or
hi
gh
m
et
ab
ol
ic
ris
k5

TC
:H
D
L-
C

H
D
L-
C

LD
L-
C

BP

H
O
M
A
-IR

C
RP
W
ho
le
-fa
ta
nd
re
du
ce
d-
fa
t
da
iry
(g
iv
en
as
sv
s/
d)
as
as
se
ss
ed
by
21
2-
ite
m
se
m
iq
ua
nt
ita
tiv
e
FF
Q
at
ba
se
lin
e
an
d
fo
llo
w
-u
p.
Re
du
ce
d-
fa
tc
la
ss
ifi
ca
tio
ns
:
m
ilk
<
3%
,c
he
es
e
<
16
%
,
bu
tt
er
<
50
%
,i
ce
cr
ea
m
<
7%
,y
og
ur
t<
3%
,
da
iry
de
ss
er
t/
cu
st
ar
d
<
3%
,
cr
ea
m
<
30
%
.
A
ge
,e
ne
rg
y
in
ta
ke
,d
ie
ta
ry
m
is
re
po
rt
in
g
st
at
us
,a
er
ob
ic
fit
ne
ss
,m
at
er
na
la
ge
,
br
ea
st
fe
ed
in
g,
di
et
ar
y
pa
tt
er
ns
,a
nd
BM
Iw
he
re
ap
pr
op
ria
te
;f
am
ily
fa
ct
or
s,
in
co
m
e,
m
ed
ic
al
hi
st
or
y
al
so
in
ve
st
ig
at
ed
.
W
ho
le
-fa
t(
sv
s/
d)
an
d
re
du
ce
d-
fa
td
ai
ry
(s
vs
/d
)
co
ns
id
er
ed
to
ge
th
er
in
m
od
el
s.
Se
pa
ra
te
an
al
ys
is
by
se
x.
In
bo
ys
:i
nc
re
as
es
in
w
ho
le
-
an
d
re
du
ce
d-
fa
td
ai
ry
bo
th
as
so
ci
at
ed
w
ith
re
du
ct
io
n
in
di
as
to
lic
BP
∗ ;
re
du
ce
d-
fa
t
da
iry
in
ta
ke
al
so
as
so
ci
at
ed
w
ith
re
du
ct
io
n
in
H
D
L-
C
∗
an
d
in
cr
ea
se
d
TC
:H
D
L-
C
∗
In
gi
rls
:n
o
si
gn
ifi
ca
nt
as
so
ci
at
io
ns
.
A
G
A
H
LS
te
Ve
ld
e
et
al
.,2
01
1
(5
3)
23
-y
fo
llo
w
-u
p
at
th
es
e
tim
e
po
in
ts
:1
4,
15
,1
6,
21
,2
7,
32
,a
nd
36
y
D
ut
ch
te
en
ag
er
s
∼1
3
y
at
ba
se
lin
e,
53
%
F
n
=
≥3
74
6
A
t3
6
y,
ab
ov
e
or
be
lo
w
m
ed
ia
n
fo
r
no
nf
as
tin
g:
•
H
D
L-
C
•
BP
Re
du
ce
d-
fa
t(
≤2
%
)o
r
w
ho
le
-fa
td
ai
ry
(>
2%
)f
ro
m
di
et
iti
an
di
et
hi
st
or
y
in
te
rv
ie
w
fo
rp
re
ce
ed
in
g
4
w
ee
ks
.
Se
x,
en
er
gy
in
ta
ke
,p
hy
si
ca
l
ac
tiv
ity
,s
m
ok
in
g
st
at
us
.
A
du
lts
w
ith
TG
ab
ov
e
th
e
m
ed
ia
n
ha
d
hi
gh
er
in
ta
ke
s
of
re
du
ce
d-
fa
td
ai
ry
at
16
y
co
m
pa
re
d
w
ith
th
os
e
be
lo
w
th
e
m
ed
ia
n.
∗
A
du
lts
w
ith
H
bA
1c
ab
ov
e
th
e
m
ed
ia
n
ha
d
hi
gh
er
m
ed
ia
n
in
ta
ke
s
of
w
ho
le
-fa
td
ai
ry
at
14
y,
co
m
pa
re
d
w
ith (C
on
tin
ue
d)
Whole- or reduced-fat dairy in children 13
D
ow
nloaded from
 https://academ
ic.oup.com
/advances/article-abstract/doi/10.1093/advances/nm
aa011/5760740 by guest on 23 April 2020
TA
BL
E
2
(C
on
tin
ue
d)
St
ud
y
an
d
re
fe
re
n
ce
Su
b
je
ct
s
O
ut
co
m
es
2
Ex
p
os
ur
e
va
ri
ab
le
s
C
on
fo
un
d
er
s
co
n
si
d
er
ed
C
on
cl
us
io
n
s3

TG
,H
bA
1c

A
da
pt
ed
M
et
S
st
at
us
7
th
os
e
be
lo
w
th
e
m
ed
ia
n.
∗
N
o
si
gn
ifi
ca
nt
as
so
ci
at
io
ns
w
ith
ot
he
ro
ut
co
m
es
.
TA
RG
et
Ki
ds
!8
W
on
g
et
al
.,
20
19
(7
1)
A
nn
ua
lf
ol
lo
w
-u
p
C
an
ad
ia
n
ch
ild
re
n
4±
2
y
(2
–8
y)
,
47
%
F
n
=
28
90
at
ba
se
lin
e.
O
nl
y
32
%
co
m
pl
et
ed
≥2
vi
si
ts
(<
4%
co
m
pl
et
ed
≥4
vi
si
ts
)

N
on
fa
st
in
g
no
n-
H
D
L-
C
9

“H
ig
h-
ris
k”
cu
t
po
in
to
f
3.
75
m
m
ol
/L
al
so
ap
pl
ie
d1
0
Q
ue
st
io
nn
ai
re
as
ke
d
pa
re
nt
s
to
1)
Re
po
rt
ty
pe
of
m
ilk
ty
pi
ca
lly
co
ns
um
ed
by
ch
ild
:s
ki
m
,
1%
,2
%
,o
rw
ho
le
(3
.2
5%
);
2)
Se
le
ct
ho
w
m
an
y
cu
ps
th
e
ch
ild
co
ns
um
es
in
a
ty
pi
ca
l
da
y
A
ge
,s
ex
,B
M
Iz
-s
co
re
,d
ai
ly
fre
e
pl
ay
,b
re
as
tfe
ed
in
g
du
ra
tio
n,
m
ot
he
r’s
et
hn
ic
ity
,f
am
ily
in
co
m
e,
pa
re
nt
al
hi
st
or
y
of
C
VD
.
Fu
rt
he
ra
dj
us
te
d
fo
rt
yp
ic
al
vo
lu
m
e
of
m
ilk
co
ns
um
ed
.
In
cr
ea
se
in
m
ilk
fa
tp
er
ce
nt
ag
e
w
as
as
so
ci
at
ed
w
ith
a
sl
ig
ht
in
cr
ea
se
in
no
n-
H
D
L-
C
in
un
ad
ju
st
ed
∗∗
an
d
ad
ju
st
ed
∗
an
al
ys
is
.
M
ilk
fa
tw
as
no
ta
ss
oc
ia
te
d
w
ith
in
cr
ea
se
d
od
ds
of
ha
vi
ng
hi
gh
no
n-
H
D
L-
C
.
O
BS
ER
VA
TI
O
N
A
L:
C
RO
SS
-S
EC
TI
O
N
A
L
(5
st
ud
ie
s)
C
A
SP
IA
N
-IV
Fa
lla
h
et
al
.,
20
16
(5
9)
Ira
ni
an
sc
ho
ol
ch
ild
re
n
12
±
3
y
(6
–1
8
y)
,
49
%
F
n
=
13
,4
86

El
ev
at
ed
BP
ba
se
d
on
pe
di
at
ric
cu
t-
po
in
ts
11
M
od
ifi
ed
qu
es
tio
nn
ai
re
12
us
ed
to
as
se
ss
w
ho
le
-fa
to
r
lo
w
-fa
tm
ilk
ty
pe
(n
ot
fu
rt
he
r
de
fin
ed
)u
su
al
ly
co
ns
um
ed
.
Se
x,
ag
e,
ph
ys
ic
al
ac
tiv
ity
,
sc
re
en
tim
e,
BM
I,
bi
rt
h
w
ei
gh
t,
m
ilk
ty
pe
in
in
fa
nc
y,
fa
m
ily
hi
st
or
y
of
hy
pe
rt
en
si
on
,a
nd
fre
qu
en
cy
of
ot
he
rf
oo
d
gr
ou
ps
co
ns
um
ed
;p
lu
s
fre
qu
en
cy
of
m
ilk
co
ns
um
pt
io
n.
U
su
al
co
ns
um
pt
io
n
of
w
ho
le
-fa
tm
ilk
w
as
no
t
as
so
ci
at
ed
w
ith
od
ds
of
el
ev
at
ed
BP
in
bo
ys
or
gi
rls
.
TL
G
S
G
ho
tb
od
di
n
M
oh
am
m
ad
ie
ta
l.,
20
15
(7
2)
Ira
ni
an
ch
ild
re
n
15
±
3
y
(1
0–
19
y)
,5
3%
F
n
=
78
5

M
et
S
13
Lo
w
-a
nd
hi
gh
-fa
td
ai
ry
(u
nd
efi
ne
d)
fro
m
a
16
8-
ite
m
1-
y
se
m
iq
ua
nt
ita
tiv
e
FF
Q
.
A
ge
,s
ex
,e
ne
rg
y,
BM
Ii
nc
lu
de
d
in
m
od
el
s
of
to
ta
ld
ai
ry
bu
t
no
co
nf
ou
nd
er
s
sp
ec
ifi
ed
fo
r
re
du
ce
d-
or
w
ho
le
-fa
td
ai
ry
an
al
ys
is
.
Ty
pe
of
da
iry
pr
od
uc
ts
co
ns
um
ed
w
as
no
t
as
so
ci
at
ed
w
ith
od
ds
of
M
et
S.
H
irs
ch
le
re
ta
l.,
20
09
(6
0)
A
rg
en
tin
ia
n
ch
ild
re
n
an
d
ad
ol
es
ce
nt
s
10
±
2
y
(5
–1
4
y)
,5
2%
F
n
=
36
5

BP

H
D
L-
C

H
O
M
A
-IR

In
su
lin

TG
3
ca
te
go
rie
s
of
w
ho
le
-fa
tm
ilk
co
ns
um
pt
io
n
(≤
1,
2–
3,
or
≥4
sv
s/
d)
,14
fro
m
pe
di
at
ric
ia
n
in
te
rv
ie
w
w
ith
m
ot
he
r.
O
nl
y
fo
rH
O
M
A
-IR
m
od
el
:
ph
ys
ic
al
ac
tiv
ity
,t
el
ev
is
io
n
vi
ew
in
g,
su
ga
r-
sw
ee
te
ne
d
be
ve
ra
ge
in
ta
ke
,p
ar
en
ta
l
ed
uc
at
io
n,
se
x,
ag
e,
H
D
L-
C
,
sy
st
ol
ic
BP
.
W
ho
le
-fa
tm
ilk
as
so
ci
at
ed
w
ith
lo
w
er
H
O
M
A
-IR
in
ad
ju
st
ed
m
od
el
s.∗
U
na
dj
us
te
d
as
so
ci
at
io
ns
ac
ro
ss
in
ta
ke
gr
ou
ps
:

Sy
st
ol
ic
BP
(in
ve
rs
e)
∗∗

H
D
L
no
ns
ig
ni
fic
an
t

H
O
M
A
-IR
(in
ve
rs
e)
∗

In
su
lin
(in
ve
rs
e)
∗

TG
no
ns
ig
ni
fic
an
t
Sa
m
ue
ls
on
et
al
.,
20
07
(7
3)
Sw
ed
is
h
ad
ol
es
ce
nt
s
∼1
5
y,
55
%
F
n
=
93

TG

TC

In
su
lin

A
po
B
(n
=
50
)

A
po
A
-1
(n
=
49
)

A
po
B:
ap
oA
-1
Se
ru
m
ch
ol
es
te
ro
le
st
er
fa
tt
y
ac
id
co
m
po
si
tio
n
(%
)f
or
15
:0
an
d
tra
ns
-1
6:
1n
–7
.
Pr
op
or
tio
n
of
di
et
ar
y
fa
tt
y
ac
id
s
ad
ju
st
ed
fo
re
ne
rg
y
in
ta
ke
(fr
om
7-
d
w
ei
gh
ed
fo
od
re
co
rd
s)
fo
r
tra
ns
-1
6:
1n
–7
.
BM
I,
ph
ys
ic
al
ac
tiv
ity
,v
eg
et
ab
le
an
d
ju
ic
e
in
ta
ke
,s
ep
ar
at
e
by
ge
nd
er
.
Se
ru
m
15
:0
%
as
so
ci
at
ed
w
ith
lo
w
er
:

TC
∗ (
F
an
d
M
)

A
po
A
-1
∗∗
(F
)

A
po
B∗
(M
)

A
po
B:
ap
oA
-1
∗ (
M
)
(C
on
tin
ue
d)
14 O’Sullivan et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/advances/article-abstract/doi/10.1093/advances/nm
aa011/5760740 by guest on 23 April 2020
TA
BL
E
2
(C
on
tin
ue
d)
St
ud
y
an
d
re
fe
re
n
ce
Su
b
je
ct
s
O
ut
co
m
es
2
Ex
p
os
ur
e
va
ri
ab
le
s
C
on
fo
un
d
er
s
co
n
si
d
er
ed
C
on
cl
us
io
n
s3
Se
ru
m
%
16
:1
n–
7
as
so
ci
at
ed
w
ith
hi
gh
er
:
•
TG
∗ (
F)
•
A
po
B∗
(M
)
•
A
po
B:
ap
oA
-1
∗ (
M
)
D
ie
ta
ry
%
16
:1
n–
7
as
so
ci
at
ed
w
ith
lo
w
er
:
•
TG
∗ (
F)
W
an
g
et
al
.,
20
11
(7
4)
U
S
ad
ol
es
ce
nt
s
∼1
5
y,
43
%
F
n
=
30
5

Se
ru
m
ad
ip
on
ec
tin

C
RP

Cy
to
ki
ne
s
(IL
-6
an
d
TN
F-
α
)

U
rin
ar
y
F2
-is
o
an
d
15
-k
et
o
Se
ru
m
ph
os
ph
ol
ip
id
s
15
:0
an
d1
7:
0.
A
ls
o
us
ed
12
7-
ite
m
FF
Q
to
ad
ju
st
fo
ro
th
er
di
et
fa
ct
or
s.
A
ge
,g
en
de
r,
et
hn
ic
ity
,T
an
ne
r
sc
or
e,
to
ta
le
ne
rg
y
in
ta
ke
,
ph
ys
ic
al
ac
tiv
ity
;d
ie
tf
ac
to
rs
:
ca
lc
iu
m
,p
ot
as
si
um
,
ph
os
ph
or
us
,v
ita
m
in
s
A
an
d
D
,ω
-3
fa
tt
y
ac
id
s,
pr
ot
ei
n,
to
ta
lfl
av
on
oi
ds
,a
nd
BM
Ii
f
ap
pr
op
ria
te
.
Se
pa
ra
te
an
al
ys
is
by
w
ei
gh
t
st
at
us
.
Se
ru
m
17
:0
an
d
15
:0
in
ve
rs
el
y
as
so
ci
at
ed
w
ith
in
fla
m
m
at
io
n
an
d
ox
id
at
iv
e
st
re
ss
∗∗
in
ov
er
w
ei
gh
t
ad
ol
es
ce
nt
s.
IL
-6
in
ve
rs
el
y
re
la
te
d
to
17
:0
an
d
15
:0
in
de
pe
nd
en
to
fw
ei
gh
t
st
at
us
.∗∗
17
:0
po
si
tiv
el
y
as
so
ci
at
ed
w
ith
ad
ip
on
ec
tin
in
ov
er
w
ei
gh
t
ad
ol
es
ce
nt
s∗
bu
ti
nv
er
se
ly
as
so
ci
at
ed
in
no
rm
al
-w
ei
gh
t
ad
ol
es
ce
nt
s.∗
N
o
si
gn
ifi
ca
nt
re
su
lts
fo
r
TN
F-
α
.
1
A
G
A
H
LS
,A
m
st
er
da
m
G
ro
w
th
an
d
H
ea
lth
Lo
ng
itu
di
na
lS
tu
dy
;B
M
I-z
,B
M
Iz
-s
co
re
;B
P,
bl
oo
d
pr
es
su
re
;C
A
SP
IA
N
,C
hi
ld
ho
od
an
d
A
do
le
sc
en
ce
Su
rv
ei
lla
nc
e
an
d
Pr
ev
en
tio
n
of
A
du
lt
N
on
co
m
m
un
ic
ab
le
di
se
as
es
;C
RP
,C
-r
ea
ct
iv
e
pr
ot
ei
n;
C
VD
,
ca
rd
io
va
sc
ul
ar
di
se
as
e;
F2
-is
o,
F2
-is
op
ro
st
an
es
;H
bA
1c
,g
ly
ca
te
d
he
m
og
lo
bi
n;
H
D
L-
C
,H
D
L
ch
ol
es
te
ro
l;
H
T,
hy
pe
rt
en
si
on
;L
D
L-
C
,L
D
L
ch
ol
es
te
ro
l;
Lp
(a
),
lip
op
ro
te
in
(a
);
M
et
S,
m
et
ab
ol
ic
sy
nd
ro
m
e;
sv
,s
er
vi
ng
;T
A
RG
et
Ki
ds
!,
Th
e
A
pp
lie
d
Re
se
ar
ch
G
ro
up
fo
rK
id
s;
TC
,t
ot
al
ch
ol
es
te
ro
l;
TG
,t
rig
ly
ce
rid
e;
TL
G
S,
Te
hr
an
Li
pi
d
an
d
G
lu
co
se
St
ud
y;
VL
D
L-
C
,V
LD
L
ch
ol
es
te
ro
l;
W
C
,w
ai
st
ci
rc
um
fe
re
nc
e;
15
-k
et
o,
15
-k
et
o-
di
hy
dr
o-
PG
F2
al
ph
a.
2
Fa
st
in
g
m
ea
su
re
s
re
po
rt
ed
fo
rb
lo
od
re
su
lts
.
3
Si
gn
ifi
ca
nc
e
le
ve
l:
∗∗
P
<
0.
01
;∗
P
<
0.
05
.
4
A
s
de
fin
ed
by
th
e
In
te
rn
at
io
na
lD
ia
be
te
s
Fe
de
ra
tio
n
pe
di
at
ric
cr
ite
ria
(7
5)
.
5
D
er
iv
ed
fro
m
th
e
da
ta
us
in
g
cl
us
te
ra
na
ly
si
s.
6
N
um
be
rs
va
rie
d
pe
rf
ol
lo
w
-u
p:
st
ar
te
d
w
ith
n
=
63
4,
fin
is
he
d
w
ith
n
=
37
4
w
ith
ad
ul
to
ut
co
m
e
m
ea
su
re
s.
Ex
ac
tn
um
be
rs
us
ed
at
ea
ch
fo
llo
w
-u
p
no
tr
ep
or
te
d.
7
M
et
ab
ol
ic
sy
nd
ro
m
e
w
as
de
fin
ed
as
th
e
pr
es
en
ce
of
≥2
/5
,a
s
ad
ap
te
d
fro
m
3/
5
ac
co
rd
in
g
to
th
e
de
fin
iti
on
,o
ft
he
fo
llo
w
in
g
co
m
po
ne
nt
s:
W
C
>
94
cm
in
M
or
>
80
cm
in
F;
TG
co
nc
en
tr
at
io
n
>
15
0
m
/d
L
(1
.6
9
m
m
ol
/L
);
se
ru
m
H
D
L-
C
<
40
m
g/
dL
(1
.0
3
m
m
ol
/L
)i
n
M
an
d
<
50
m
g/
dL
(1
.2
9
m
m
ol
/L
)i
n
F;
sy
st
ol
ic
BP
>
13
0
m
m
H
g
an
d/
or
di
as
to
lic
BP
>
85
m
m
H
g;
H
bA
1c
>
6.
2%
(7
6)
.
8
A
lth
ou
gh
th
is
st
ud
y
is
re
po
rt
ed
as
a
lo
ng
itu
di
na
ls
tu
dy
,i
tw
as
tr
ea
te
d
as
cr
os
s-
se
ct
io
na
lf
or
th
e
pu
rp
os
es
of
th
is
re
vi
ew
be
ca
us
e
th
e
re
la
tio
n
be
tw
ee
n
da
iry
fa
ti
nt
ak
e
an
d
no
n-
H
D
L-
C
w
as
as
se
ss
ed
cr
os
s-
se
ct
io
na
lly
w
ith
in
th
e
an
al
ys
es
(3
2%
of
su
bj
ec
ts
pr
ov
id
ed
da
ta
fro
m
2
vi
si
ts
,<
4%
fro
m
≥4
vi
si
ts
):
“…
ge
ne
ra
liz
ed
es
tim
at
in
g
eq
ua
tio
ns
w
ith
an
ex
ch
an
ge
ab
le
co
rr
el
at
io
n
st
ru
ct
ur
e,
w
hi
ch
ta
ke
s
in
to
ac
co
un
tp
ot
en
tia
lc
or
re
la
tio
n
w
ith
in
su
bj
ec
ts
w
ith
re
pe
at
ed
m
ea
su
re
s.”
9
C
al
cu
la
te
d
by
su
bt
ra
ct
in
g
H
D
L-
C
fro
m
TC
.
10
Cu
tp
oi
nt
s
w
er
e
ba
se
d
on
th
e
U
S
N
at
io
na
lH
ea
rt
,L
un
g,
an
d
Bl
oo
d
In
st
itu
te
Ex
pe
rt
Pa
ne
lo
n
In
te
gr
at
ed
G
ui
de
lin
es
fo
rC
ar
di
ov
as
cu
la
rH
ea
lth
an
d
Ri
sk
Re
du
ct
io
n
in
C
hi
ld
re
n
an
d
A
do
le
sc
en
ts
(7
7)
.
11
El
ev
at
ed
BP
w
as
ca
te
go
riz
ed
as
pr
e-
H
T
an
d
H
T
ac
co
rd
in
g
to
th
e
Fo
ur
th
Re
po
rt
of
th
e
W
or
ki
ng
G
ro
up
on
Bl
oo
d
Pr
es
su
re
Co
nt
ro
li
n
C
hi
ld
re
n
(7
8)
.P
re
-H
T
w
as
co
ns
id
er
ed
as
ei
th
er
BP
eq
ua
lt
o
or
gr
ea
te
rt
ha
n
th
e
ag
e-
an
d
ge
nd
er
-s
pe
ci
fic
90
th
pe
rc
en
til
e
af
te
ra
dj
us
tin
g
fo
rw
ei
gh
ta
nd
he
ig
ht
,o
ra
s
BP
≥1
20
/8
0
m
m
H
g.
W
he
n
BP
w
as
eq
ua
lt
o
or
gr
ea
te
rt
ha
n
th
e
ag
e-
an
d
ge
nd
er
-s
pe
ci
fic
95
th
pe
rc
en
til
e
va
lu
e,
it
w
as
co
ns
id
er
ed
as
H
T.
12
W
H
O
G
lo
ba
ls
ch
oo
l-b
as
ed
st
ud
en
th
ea
lth
su
rv
ey
,fi
lle
d
ou
tb
y
st
ud
en
ts
un
de
rt
he
su
pe
rv
is
io
n
of
st
aff
an
d
th
e
pr
es
en
ce
of
≥1
pa
re
nt
.
13
M
et
S
de
fin
ed
as
ha
vi
ng
≥3
of
th
e
fo
llo
w
in
g
co
m
po
ne
nt
s:
fa
st
in
g
pl
as
m
a
gl
uc
os
e
co
nc
en
tr
at
io
n
≥1
10
m
g/
dL
;f
as
tin
g
se
ru
m
TG
≥1
00
m
g/
dL
;H
D
L-
C
<
45
m
g/
dL
fo
rb
oy
s
ag
ed
15
–1
9
y
an
d
<
50
m
g/
dL
fo
ro
th
er
pe
op
le
;W
C
>
75
th
pe
rc
en
til
e
fo
r
th
e
ag
e
an
d
se
x
of
Ira
ni
an
po
pu
la
tio
n;
sy
st
ol
ic
an
d
di
as
to
lic
BP
>
90
th
pe
rc
en
til
e
fo
ra
ge
,s
ex
,a
nd
he
ig
ht
ba
se
d
on
th
e
re
co
m
m
en
da
tio
ns
of
th
e
N
at
io
na
lH
ea
rt
,L
un
g
an
d
Bl
oo
d
In
st
itu
te
.
14
Re
co
m
m
en
de
d
se
rv
in
g
of
m
ilk
pe
rd
ay
w
as
2
cu
ps
fo
rc
hi
ld
re
n
ag
ed
4
to
8
y,
an
d
3
cu
ps
fo
rc
hi
ld
re
n
ag
ed
9
to
18
y
(6
7)
.
Whole- or reduced-fat dairy in children 15
D
ow
nloaded from
 https://academ
ic.oup.com
/advances/article-abstract/doi/10.1093/advances/nm
aa011/5760740 by guest on 23 April 2020
cream cheese, yogurts, and milk-based desserts. This gave a
more accurate assessment of total dairy intake than a focus
on milk alone. Confounders considered were sex, energy
intake, physical activity, and smoking status. No significant
associations with measures of adiposity were observed
for low- or high-fat dairy intake at any adolescent time
points.
The Growing Up Today study was 1 of the largest study
cohorts we reviewed, with almost 12,000 participants aged
9–14 y at baseline followed for 3 y (45). This study, investi-
gating the children of Nurses’ Health Study II participants,
reported no significant association between dairy fat intake
as measured by an annual 1-y FFQ and yearly change in
self-reported BMI. The authors also reported sex differences
in association with milk consumption—consumption of
1% milk in boys was significantly (P < 0.05) positively
associated with BMI gain over a year [BMI change per
8 oz (244 g) serving, β = 0.027; 95% CI: 0.002, 0.053],
whereas in girls a significant (P < 0.05) positive association
was found with skim milk (BMI change per serving, β =
0.021; 95% CI: 0.001, 0.040). Whole-fat and 2% milk were
not significantly associated with BMI gain in either boys
or girls.
Differing associations by sex were also noted in a
prospective study of genetically identical twin pairs with
shared environments (48). Variation in dietary intake at age
9 y between sets of twins was compared with subsequent
differences in BMI at age 14 y. Within girl twin sets,
those consuming more reduced-fat milk were more likely
to positively increase BMI over time (Spearman ρ = 0.32,
P< 0.05); however, no significant associations were observed
in boys (Spearman ρ = 0.09, P> 0.05), or for whole-fat milk
(for girls, Spearman ρ = −0.16, P> 0.05; for boys, Spearman
ρ = 0.17, P > 0.05) (48).
The remaining prospective studies showed no significant
associations of whole-fat dairy or reduced-fat dairy con-
sumption with adiposity outcomes in any models (21, 50) or
in fully adjusted models (51).
Most cross-sectional studies examining both whole- and
reduced-fat dairy consumption in relation to adiposity
measures reported that consumption of dairy with higher
fat content was associated with lower risk of obesity (47,
50, 52, 55, 58, 62) (Table 1). The remaining cross-sectional
studies examining consumption of both whole- and reduced-
fat dairy products reported no significant associations with
measures of adiposity for either type (63–65).
The majority of the cross-sectional studies examining
dairy fat or whole-fat dairy intake (not in comparison with
reduced-fat dairy) showed an inverse association with ≥1
measure of obesity (54, 56, 60, 61), whereas another showed
that being in a diet cluster characterized by a high whole-fat
milk intake was not associated with obesity measures (57)
(Table 1).
The study by Nezami et al. (63) utilized the widest range
of adipositymeasures, including BMI z-score, weight z-score,
waist-to-height ratio, BMI categories, and percentage fat and
fat-free mass from bioelectrical impedance analysis (BIA)
scales, to investigate cross-sectional associations with obesity
measures in ethnically diverse US adolescents participating
in the Teen Food and Development Study. Intake of whole-
fat, reduced-fat, and nonfat milk was assessed using a
151-item semiquantitative FFQ. Other dairy including
cheese and sweetened dairy was also considered but was
not separated according to fat content. Models were run
separately by gender and adjusted for age, site (2 sites used),
ethnicity, energy intake, maternal education, soda intake,
physical activity, and milk substitute intake. Although total
dairy intake in boys was positively associated with waist-to-
height ratio, fat-free mass, and fat mass, the fat content of
the milk consumed was not associated with any measures
investigated.
We cannot discount the potential for reverse causality,
particularly in the cross-sectional studies. Children who are
overweight or obese, or have a family history of obesity could
be more likely to be provided with reduced-fat dairy in an
effort to reduce caloric intake. In contrast, children who
are underweight could be more likely to be given whole-
fat dairy foods. In an effort to control for this potential
effect in prospective studies, many controlled for baseline
and/or familial adiposity measures (Table 1). Additionally,
2 studies limited their analysis to participants who were not
overweight at baseline (49, 52). As is the case for this literature
overall, studies that took baseline adiposity into account,
by adjusting for it or by conducting stratified analyses,
indicate that whole-fat dairy is either inversely or not
associated with adiposity measures independent of baseline
adiposity.
Most studies included in this review relied on BMI or BMI
z-scores as a proxymeasure of adiposity, with only 5 using fat
mass based on eitherDXA (46, 50, 53) or BIA (21, 63). Results
for those studies using DXAwere similar to the other studies
using BMI as an end point: either whole-fat but not reduced-
fat dairy was either inversely associated with percentage
fat mass longitudinally (46) or cross-sectionally (50); or
neither type showed significant associations longitudinally
(50, 53). Results for both studies using BIA showed no
significant associations between body fat mass and whole-fat
or reduced-fat dairy intake.
Overall, a review of the available evidence suggests that
consumption of whole-fat dairy products, or dairy fat intake,
is not associated with an increase in adiposity measures.
Conversely, some studies reported positive associations
with intake of reduced-fat dairy, and inverse associations
with whole-fat dairy intake. These findings suggest that
consumption of reduced-fat dairy over whole-fat dairy is
unlikely to prevent obesity or to reduce excess adiposity in
children.
Whole-fat and reduced-fat dairy and cardiometabolic
disease risk biomarkers in children
Ten studies were identified that investigated the relation
between dairy intake by fat content and ≥1 cardiometabolic
disease risk biomarker, with some studies applyingmetabolic
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syndrome classifications or using clustering to group high-
risk children together.
Serum lipids and apolipoproteins.
Our review identified 1 randomized controlled trial that in-
vestigated these outcomes. Hendrie and Golley (43) showed
that changing from whole- to reduced-fat dairy products
for 12 wk did not result in a significant change to LDL
cholesterol, HDL cholesterol, TC, or triglycerides over this
period. Similarly, the other (nonrandomized) controlled
trial by Villalpando and colleagues (44) also reported no
change in TC:HDL cholesterol when children in Mexican
boarding schools were switched from whole-fat to reduced-
fat or skim milk, because both LDL cholesterol and HDL
cholesterol were reduced. Only 1 prospective observational
study reported TC:HDL cholesterol, finding a significant
positive relation with reduced-fat (but not whole-fat) dairy
intake over time in boys, but not girls [each additional serving
of reduced-fat dairy was associated with a 2% increase in the
total:HDL cholesterol ratio (95%CI: 1.002, 1.03)]. This could
have been due to a significant inverse association between
reduced-fat dairy intake and fasting plasma HDL cholesterol
(51).
Non-HDL cholesterol (as calculated by TC minus HDL
cholesterol) was found to be positively associated with
percentage ofmilk fat typically consumed in a largeCanadian
study (each percentage increase in milk fat was associated
with a 0.024-mmol/L increase in non-HDL cholesterol;
P = 0.01) (71), although the relation with HDL choles-
terol was not reported. For triglycerides, studies reported
an inverse association with whole-fat dairy (participants
with a triglyceride concentration below the median at age
36 y consumed significantly more whole-fat dairy at 16 y,
averaging∼400 g/wkmore, P= 0.030) (53), or no significant
association (60). The dairy fatty acid 16:1n–7 was positively
correlatedwith triglycerides when assessed in terms of serum
cholesterol ester fatty acid composition percentage (Pearson
r= 0.30,P< 0.05), but negatively associatedwhen assessed as
percentage energy in the diet (Pearson r = −0.32, P < 0.05),
in Swedish adolescent girls (73). The same study also showed
dairy biomarker serum 15:0 was associated with lower TC
in boys and girls (Pearson r= −0.34 and−0.32, respectively,
P< 0.05). Other studies did not show significant associations
with TC or individual lipid measures.
Two studies investigated apoA-1 and apoB. The Mexican
boarding school controlled trial by Villalpando et al. (44)
demonstrated that both apoA-1 and apoB decreased signif-
icantly in children who switched from whole- to reduced-
fat milk, with no significant change to the ratio (change
coefficient = −0.02, P = 0.15). Conversely, children who
switched to skim (defatted milk) showed significantly lower
apoB but not apoA-1, resulting in a significant decrease
in the apoB:apoA-1 ratio (change coefficient = −0.05,
P = 0.001). The potential complexities of the relation
between lipoproteins and dairy intake were highlighted by
the only other study that included apoA-1 and apoB as end
points, a cross-sectional analysis of Swedish adolescents by
Samuelson and colleagues (73). Serum cholesterol ester fatty
acid composition (percentage) for 1 dairy fat–related fatty
acid (pentadecanoic acid, 15:0) was significantly inversely
associated with the apoB:apoA-1 ratio in boys (correlation
coefficient= −0.50, P< 0.05) but not girls (data not shown).
However, another serum fatty acid linked to dairy fat intake
(trans-palmitoleic acid, trans-16:1n–7) was associated with a
significant positive association with the apoB:apoA-1 ratio in
boys (correlation coefficient = 0.45, P < 0.05).
Blood pressure.
There were no randomized controlled trials identified in this
review that investigated effects of whole-fat dairy on blood
pressure. Among the 2 prospective studies, the Australian
Raine Study demonstrated that increases in both whole- and
reduced-fat dairy intake were similarly associated with a
reduction in diastolic blood pressure in boys from early to
late adolescence (mean reduction in diastolic blood pressure
of 0.47–0.66 mmHg, P< 0.05) (51), whereas the Amsterdam
Growth and Health Longitudinal Study found no significant
association in teenagers that were followed through to
adulthood (53).
One cross-sectional study of Iranian schoolchildren
focused only on blood pressure as an outcome, with a
very large sample size (n = 13,486) and comprehensive
statistical models (59). Consumption of whole-fat milk was
not associated with odds of elevated systolic or diastolic
blood pressure in boys or girls, based on pediatric cut-points.
Intake of dairy outside of milk was not considered. The
only other cross-sectional study investigating blood pressure
found that those children consuming≥4 glasses of whole-fat
milk/d had significantly lower systolic blood pressure than
those consuming ≤1 glass/d (95.8 ± 12.3 compared with
90.2 ± 10.8 mmHg, P < 0.05) although this analysis did not
include an adjustment for potential confounding factors (60).
Inflammation and oxidative stress.
We found 2 studies that investigated relations between
whole- and reduced-fat dairy intake and fasting plasma CRP,
1 of which was the only study to investigate cytokines and
adiponectin along with measures of oxidative stress. One
prospective study found no association between the intake
of whole- or reduced-fat dairy and fasting plasma CRP
concentrations (51). In the other study, a cross-sectional
investigation, higher concentrations of serum phospholipid
dairy fatty acids (17:0 and 15:0) were associated with lower
IL-6 among adolescents, in adjusted analyses with other
dietary confounders considered (P-trend across quintiles
<0.001) (74). Obesity appeared to modify the relations—
dairy fatty acids were inversely associated with CRP, and
positively associated with adiponectin (17:0) in overweight,
but not in normal-weight adolescents (P-trend <0.01). No
significant associations were observed for TNF-α.
Indices of glucose metabolism.
No data on effects of whole-fat dairy consumption on indices
of glucose metabolism were available from controlled trials.
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In prospective studies, adults with HbA1c values above the
median had reported higher intakes of whole-fat dairy at
14 y (∼450 g/wk higher, P = 0.013), compared with those
below the median, in the Amsterdam Growth and Health
Longitudinal Study (53). No significant associations with
intakes of any type of dairy were observed for HOMA-IR
from early to late adolescence in the Raine Study (51). In
a cross-sectional study of children and adolescents from
lower socioeconomic suburbs of Buenos Aires, category
of whole-fat milk intake (≤1 glass/d, 2–3 glasses/d, and
≥4 glasses/d, glass volume not defined) was inversely
associated with HOMA-IR in adjusted models (β = −0.135,
P < 0.05), and with fasting insulin (uU/mL) in unadjusted
models (from lowest to highest, respectively, 4.59 ± 4.79,
3.61 ± 3.49, 2.34 ± 1.33; P = 0.03; adjusted model only
performed for HOMA-IR) (60). Reduced-fat milk intake was
not considered in this study, because reduced-fat milk was
more expensive and therefore considered by the authors
to be unobtainable by most study participants. Although
confounders were included in the adjusted model (physical
activity, television viewing, sugar-sweetened beverage intake,
parental education, sex, age, along with HDL cholesterol and
systolic blood pressure), it could be hard to separate the
effects of socioeconomic status, which could be particularly
relevant in this population: ∼16% of the families did not
have a refrigerator, and 9% had a dirt floor in their home.
In a relatively higher socioeconomic status group of Swedish
adolescents, dairy fat–related fatty acids measured in either
serum or diet were not significantly associated with serum
insulin concentrations (73).
Discussion
In children, is consumption of whole-fat dairy products
or dairy fat associated with higher measures of
adiposity? Do associations differ for reduced-fat dairy
intake?
Despite the wide range of methods employed over a diverse
range of populations in the studies investigated, results were
unanimous in showing that whole-fat dairy products were
not associated with increased risk of weight gain or measures
of adiposity. On the contrary, some observational studies
identified a significant inverse relation that was not similarly
seen for reduced-fat dairy intake (45–50, 52, 54, 58, 62). Our
results agree with a previous review of dairy and obesity
in children (19), and with a meta-analysis of randomized
controlled studies with healthy adults (79), which found
similar associations for both whole- and reduced-fat dairy.
Consumption of whole-fat dairy products rather than
reduced-fat varieties could result in increased feelings of
satiety. In a randomized crossover trial, 48 Iranian children
consumed a breakfast with either skim milk or whole-fat
milk for 2 d (80). Children reported a higher satiety score
4 h after drinking whole-fat milk with breakfast compared
with skimmilk. Young children are considered to be naturally
good at regulating their own appetite (81), and our results
suggest that including whole-fat dairy as part of the diet does
not promote overconsumption of energy or weight gain. In
both the 2 controlled trials included in this review, overall
dietary energy intake remained similar in children changing
from whole-fat to reduced-fat dairy (43, 44). If children
decrease dairy fat in their diet, the source of the subsequent
compensatory calories could determine whether there is any
overall net effect on body weight. This could potentially
explain the variation in some studies finding an increased
risk of obesity for reduced-fat dairy products, compared with
whole-fat dairy.
In children, is consumption of whole-fat dairy products
or dairy fat associated with increased cardiometabolic
risk? Do associations differ for reduced-fat dairy intake?
The research was less conclusive in the area of car-
diometabolic risk biomarkers. Although almost all evidence
from the observational studies suggested that consumption
of whole-fat dairy was not associated with increased risk, a
change from whole-fat to reduced-fat dairy in the 2 trials
identified was associated with either no significant change
over the study period (43) or improved outcomes for some
(but not all) risk factors (44). Both of these trials included
children over a wide range of ages, including puberty.
This wide range makes it difficult to determine whether
differences exist prior to puberty.
Within the studies investigating cardiometabolic risk,
7 reported data on blood lipids, of which only 3 investigated
lipid ratios [TC:HDL cholesterol (44, 51) or apoB:apoA-
1 ratios (44, 73)]. Although trials in this review noted a
decrease in LDL cholesterol when changing from whole-
fat to reduced-fat dairy (43, 44), the lack of change to the
ratio of TC:HDL cholesterol (44) [Hendrie and Golley (43)
did not report any ratios] suggests there could have been
no or only minimal change to overall cardiovascular risk
based on serum lipids. However, the ratio of apoB:apoA-1
was observed to fall by Villalpando et al. (44) in a change
from whole-fat to skim milk, representing a more extreme
change in dairy fat intake. Changes in energy intake from
milk were compensated for in these children by increased
intakes of tortillas (low glycemic index, high-fiber, lime-
treated whole cornmeal pancakes), which might have also
affected lipid profiles. Potential limitations of this study
included nonrandomized groups and differing provision of
liquid milk to the skim milk group, whereas the reduced-fat
and whole-fat groups received powdered milk.
Chronic inflammation and oxidative stress are linked
with a range of disease processes, including cardiovascular
disease, diabetes, certain types of cancer, and cognitive
impairment (82). This review found no evidence that
the consumption of whole-fat dairy foods increases in-
flammation biomarkers. Indeed, higher concentrations of
biomarkers of dairy fat consumption were associated with
lower chronic inflammation, as represented by IL-6 (74).
In overweight, but not normal-weight adolescents, dairy fat
intake biomarkers were associated with beneficial higher
adiponectin concentrations (74). Adiponectin is considered
to play an important role in glucose and lipid metabolism,
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with insulin-sensitizing and anti-inflammatory properties
(83). Although most studies investigating cardiometabolic
outcomes included BMI in their modeling, few investigated
weight as a potential effect modifier. This could affect
associations observed, because adipose tissue is an active
endocrine organ, and children with excess adipose tissue
could have differing responses to dairy fat.
Results of studies could also be affected by the processing
of the dairy consumed. In our review, 2 studies reported
a net detrimental effect of whole-fat dairy: the Villalpando
et al. (44) trial in Mexico, which reported that changing to
skim dairy improved LDL cholesterol and the apoB:apoA-1
ratio (although HDL cholesterol decreased); and the Wong
et al. (71) observational study in Canada, which reported
a positive association with non-HDL cholesterol (although
HDL cholesterol and cholesterol ratios were not reported).
The Mexican Villalpando et al. (44) trial supplied milks
with different processing techniques applied—the skim milk
was provided in ready-to-consume liquid form, whereas the
whole-fat and 2% fat milks were supplied in powdered form.
Powdering, along with ultra-high-temperature processes,
can alter the composition of the milk slightly, affecting
milk properties and fat content (84). Fat-soluble vitamins
in dairy are reduced by removing dairy fat. However, in
the Villalpando et al. (44) trial the reduced-fat and skim
milks were subsequently fortified, including with fat-soluble
vitamins A and D. In this study, the reduced-fat milk had
almost 25%more vitamin A than the normal whole-fat milk,
adding an additional point of difference beyond fat content.
Fortification with vitamin A is also required for reduced-fat
or skimmilk inCanada, with vitaminD fortification required
for all milk. This addition of removed fat-soluble vitamins
does not occur in someother countries, such asAustralia, and
could partially contribute to differences observed between
studies.
Bovine feeding practices also differ between countries,
resulting in variations in the fatty acid composition of dairy.
Cows fed a diet based on organic grass and legumes produce
milk with higher concentrations of ω-3 and conjugated
linoleic acid compared with cows fed a conventional diet
higher in grain (85). Most dairy cows on US farms are
fed in this conventional manner, in contrast to cows in
Australia, Argentina, and the United Kingdom, which are
predominantly grass fed. However, our results showed that
beneficial associationswith dairy fat were observed in a range
of countries with differing feeding practices, including from
Australia, Argentina, Italy, Sweden, and the United Kingdom
along with Canada and the United States (Tables 1 and 2).
From the existing evidence, our ability to assess causality
is extremely limited. Randomized controlled trials provide
a robust design for providing causal evidence, but we only
identified 1 in this area. Residual confounding is inevitably a
problem in observational studies. One issue with an exposure
such as dairy fat is that animal fat intake is very strongly
associated with an unhealthy lifestyle in certain Western
countries (e.g., United States), but not necessarily in others,
such as some developing countries (86). For example, in the
Australian Raine Study, data-driven factor analysis identified
a distinct “Western” dietary pattern in the adolescent cohort,
consisting of high intakes of whole-fat dairy along with
takeaway foods, red meats, and processed meats (87). Strong
associations with other unhealthy dietary or lifestyle factors
could increase the likelihood of residual or unmeasured
confounding (10). In addition, a lower saturated fat intake
could result in changes to other aspects of the diet tomaintain
energy balance. This could be detrimental to health, de-
pending on the replacement foods. Replacement of saturated
fat with refined carbohydrate or ω-6 polyunsaturated fats
(without also increasing ω-3 fats) is proposed to lead to
an increased risk of cardiovascular disease or death (88–
90). In the 2 controlled trials we identified, decreasing dairy
fat did not occur in isolation—Villalpando et al. (44) noted
tortilla consumption increased, and Hendrie and Golley (43)
noted that carbohydrate intake as a percentage of total energy
increased.
Dietary biomarkers
Only 2 studies in our review used established biomarkers
for dairy fat intake. The low use of biomarkers is likely
due to subject burden and cost. Wang et al. (74) found
that serum phospholipids 15:0 and 17:0 were inversely
associated with inflammation and oxidative stress markers
in adolescents, but for most of the risk factors only in those
who were overweight. The authors suggest that the effects
were more noticeable in those who were overweight because
excess adiposity is known to be associated with low-grade
inflammation. Samuelson et al. (73) showed a difference
dependent on which type of biomarker was considered:
15:0 was inversely correlated with the apoB:apoA-1 ratio
in boys, whereas trans-16:1n–7 was positively associated
with the apoB:apoA-1 ratio. Given that 15:0 and trans-
16:1n–7 are both considered representative for the same
exposure (i.e., dairy fat), the discrepancy in direction of
the associations observed suggests either a lack of biological
plausibility or potential limitations in the use of these
biomarkers to represent dairy fat intake. In addition, growth
and maturation can also influence the utility of specific
biomarkers in studies of children and adolescents (91).
Comparison with the adult literature
The results from our review are similar to previous reviews in
adult populations. A systematic review and meta-analysis of
adult cohort studies reported that whole-fat dairy intake was
not significantly associated with changes in bodyweight (92).
In addition, a meta-analysis of randomized studies in adults
found no detrimental effects of whole-fat dairy, with changes
in cardiometabolic risk factors similar for both reduced-fat
and whole-fat dairy interventions (79). A 2018 systematic
review of prospective studies investigated the association
between circulating dairy fat biomarkers at baseline and risk
of cardiovascular events during follow-up. The review found
15:0was associatedwith lower risk of heart failure butwas not
associated with total cardiovascular disease, coronary heart
disease, or stroke. Those with higher intakes of 17:0 had a
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lower risk of cardiovascular disease, whereas no significant
associations were observed with trans-16:1n–7.
Quality of adiposity measures
Many studies in this review relied on BMI as a measure of
adiposity. Although BMI is cheap and easy to measure, it
is a measure of weight relative to height, rather than excess
body fat. It does not take into consideration fat mass and fat-
free mass. A study comparing BMI with fat mass and fat-
free mass from DXA in healthy 5 to 18-y-olds found that
the accuracy of BMI as a surrogate measure of adiposity in
children varies according to age, gender, degree of adiposity,
and ethnicity (93). Both weight gain and an increase in BMI
over time are part of a normal, healthy development for
children. BMI z-score accounts for age and gender, relative
to an external reference, and is considered appropriate for use
as a marker of adiposity on a single occasion (94). However,
it has limitations for measuring change, because the within-
child variability over time depends on the child’s initial level
and the reference standards used. Due to the periods of
dynamic changes over childhood growth, the stability of BMI
or BMI percentiles can bemore appropriate (94). In addition,
BMI z-score has been proposed to be a poor metric to use
in children with severe obesity, because it is only weakly
associated with other measures of body fatness (95). Despite
these potential limitations, our review showed that results
did not differ by markers of adiposity, with whole-fat dairy
showing either beneficial or no associations with BMI, BMI
z-score, or body composition measures (DXA or BIA).
Potential for publication bias
In systematic reviews, publication bias generally refers to
the underreporting of trials that did not find a significant
difference. Bias is said to occur if the results of published
studies systematically differ from the results of unpublished
studies. We did not specifically search trial registries and
other sources to identify nonpublished studies. However, we
observed that just under half of our studies reported limited
or no significant differences, suggesting that publication bias
due to insignificant results is unlikely to have a major impact
on our findings.
Generalizability
The subject groups in the studies reviewed covered wide
ranges in terms of age and location. Because studies only
included healthy subjects, results cannot be generalized to
children who are suffering from disease. Although many
studies adjusted for sex in statistical models, most did not
present associations separately for boys and girls. Of those
studies that did report separate results for boys and girls,
almost all reported differing associations in terms of the
strength of associations (45, 48, 51, 59, 73). Notably, these
studies included children with age ranges into the teens,
indicating that puberty and hormone differences could play
a role in the relation between dairy fat intake and health
outcomes. Apart from potential sex differences in adolescent
cohorts, no trends were observed between different age
groups and outcomes. Adiposity could be another poten-
tial effect modifier. In the only study that stratified by
weight status (74), beneficial associations between dairy fat
biomarkers and inflammatory and oxidative stress markers
were observed in overweight, but not in normal-weight
adolescents. This suggests that potential beneficial effects of
dairy fat might be more noticeable in children who suffer
from obesity-associated low-grade chronic inflammation.
Recommendations and conclusion
This review has highlighted the lack of randomized con-
trolled trials investigating health effects of whole- compared
with reduced-fat dairy in children. This type of study design
is considered to provide themost robust and reliable evidence
because it minimizes biases in the assessment of dietary
intakes as well as the risk of confounding inherent in
observational studies (96). Cross-sectional studies provided
the bulk of evidence in this review, and care must be taken
when interpreting results given the potential for reverse
causation. For example, parents of a child who is overweight
might prefer to provide reduced-fat dairy rather than whole-
fat dairy, with the intention of reducing overall caloric intake.
The only previous randomized controlled trial investigated
BMI andwaist circumference as indirectmarkers of adiposity
(43), but did not directly assess body composition. To date,
there have also been no published randomized controlled
trials in children investigating body composition through
DXA or whole-body densitometry. Future studies using
these body composition assessments would provide a more
precise measure of adiposity than BMI. In addition, few
pediatric studies have used biomarkers of dairy fat intake
to assess exposure to whole-fat dairy intake, which would
help validate dietary intake data. Observational studiesmight
also benefit from using nutrient density–adjusted exposure
variables (i.e., dairy intake as percentage of total energy,
rather than servings or grams per day). This would help
minimize biases affecting the dietary assessment, including
over- and underreporting (97). It would also enable studies
of substitution effects that provide estimates of differential
health effects of replacing specific dairy food calories with
other food calories (98). Thorough exploration of these
factors is important in the context of population health.
At the time of writing, we are aware of 2 pediatric
randomized controlled trials investigating dairy fat that are
currently underway, 1 in Australia, the Milky Way Study
(99), and 1 in Canada, the Cow Milk Fat Obesity Prevention
Trial (100). Further, consideration also needs to be given
to the type of dairy product consumed, to questions of
production or processing—for example, whether cows are
predominantly grass fed or grain fed—and to potential effect
modification by sex, puberty status, and adiposity category.
Obesity in childhood is described as a complex and
growing public health problem, increasing risk of chronic
disease, disability, and psychosocial consequences (101). In
the context of cardiovascular disease risk, abnormalities in
lipoprotein metabolism are noted as among the key factors
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in atherogenesis, representing ∼50% of the population-
attributable risk of developing cardiovascular disease (102).
Even small differences in dietary effects are likely to have
a meaningful impact at the population level, so it is
important that our dietary guidelines around dairy fat intake
in childhood are based on evidence from well-designed
controlled studies.
Overall, our review suggests that dietary recommenda-
tions to limit consumption of whole-fat dairy products in
children are not supported by the existing, relatively limited
evidence in the areas of adiposity or cardiometabolic disease.
However, it must be noted that the current body of evidence
on this topic has many limitations, including a lack of good
quality randomized controlled trials directly comparing the
impact of consuming diets rich in whole-fat compared with
reduced-fat dairy foods.
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